Novartis MS drug shows promising results
Basel, October 1, 2005 Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication, for the treatment of patients with relapsing multiple sclerosis (MS). ...... The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that both patient groups taking FTY720 (1.25 mg and 5 mg) who had experienced a reduction...BIDMC investigator receives Novartis Award in Diabetes
BOSTON Endocrinologist Christos S. Mantzoros, MD, Director of the Human Nutrition Research Unit at Beth Israel Deaconess Medical Center (BIDMC), received the 2005 Novartis Award in Diabetes (Young Investigator) in a presentation held June 13, 2005, at the 65th Scientific Sessions of the American Diabetes Association in San Diego, California.... ...The annual Young Investigator award is sponsored...American Urological Association honors Novartis Pharmaceuticals with annual health science award
LINTHICUM, MD, May 11, 2005: The American Urological Association (AUA) has announced that Novartis Pharmaceuticals Corporation is the 2005 recipient of the AUA Health Science Award. The award will be given at the annual awards banquet during the 100th Annual Scientific Meeting of the AUA in San Antonio later this month....... The AUA Health Science Award is given each year to one company that bes...